Related Experiment Video
Updated: Jul 14, 2026

Creating Dynamic Images of Short-lived Dopamine Fluctuations with lp-ntPET: Dopamine Movies of Cigarette Smoking
Published on: August 6, 2013
Association between dopamine transporter genotypes and smoking cessation: a meta-analysis
John A Stapleton1, Gay Sutherland, Colin O'Gara
1Tobacco Research Group, Department of Psychological Medicine, Kings College London, Institute of Psychiatry, London, UK. john.stapleton@iop.kcl.ac.uk
The dopamine transporter (DAT1) 3'UTR VNTR gene variant is linked to a 20% increased likelihood of smoking cessation. This genetic factor may indicate lower tobacco dependence, aiding individuals in quitting smoking.
Area of Science:
- Genetics
- Neuroscience
- Addiction Research
Background:
- The dopamine transporter (DAT1, SLC6A3) plays a crucial role in dopamine signaling, influencing reward pathways implicated in nicotine addiction.
- Genetic variations, specifically the 3' untranslated region (3'UTR) variable number of tandem repeats (VNTR) polymorphism in DAT1, have been investigated for their potential association with smoking behaviors.
Purpose of the Study:
- To systematically review and meta-analyze the existing evidence on the association between DAT1 3'UTR VNTR genotypes and smoking cessation success.
- To determine if specific DAT1 genotypes confer a higher or lower probability of quitting smoking.
Main Methods:
- A meta-analysis was conducted, pooling data from five studies comprising seven cohorts and a total of 2155 subjects.
- Studies included cross-sectional population surveys and smoking cessation treatment programs with follow-up data.
- Data were analyzed to compare smoking cessation rates between individuals with and without the variant 9-repeat allele of the DAT1 3'UTR VNTR.
Main Results:
- Four out of five studies indicated a trend towards higher cessation rates in individuals carrying the variant 9-repeat allele.
- The overall pooled odds ratio favored cessation for the variant 9-repeat allele (OR = 1.15, 95% CI = 0.97-1.37).
- A refined analysis using adjusted odds ratios and treating cohorts separately yielded a pooled odds ratio of 1.20 (95% CI = 1.01-1.43), suggesting a statistically significant 20% increase in the odds of smoking cessation for carriers of the 9-repeat allele.
Conclusions:
- The findings support a significant association between the DAT1 3'UTR VNTR polymorphism and smoking cessation.
- Carrying one or more variant 9-repeat alleles, compared to the common 10-repeat allele, is associated with an increased likelihood of successful smoking cessation.
- This genetic predisposition may reflect lower nicotine dependence, thereby facilitating cessation efforts.
Related Concept Videos
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Human Genetics
The complex relationship between genetics and psychology is observable through common biological components such...
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
Drugs Acting on Autonomic Ganglia: Stimulants
Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating sympathetic or...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Pharmacogenomics: Identification of New Drug Targets